Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Research Objective
2.2 Assumptions & Limitations
2.2.1 Assumptions
2.2.2 Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising incidence of chronic health problems (Impact weightage: 35%)
4.2.2 Technological improvements (Impact weightage: 35%)
4.2.3 Increasing geriatric population (Impact weightage: 20%)
4.2.4 Improved reimbursement policies in developed countries (Impact weightage: 10%)
4.3 Restrains
4.3.1 Lack of skilled or trained physicians (Impact weightage: 60%)
4.3.2 High cost of nerve stimulation therapy (Impact weightage: 40%)
4.4 Opportunity
4.4.1 Increasing popularity of minimally invasive procedures across the globe
4.5 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat on New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D and Designing
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Nerve Stimulator Market by Type
6.1 Introduction
6.2 Deep Brain Stimulator (DBS)
6.3 Vagus Nerve Stimulator (VNS)
6.4 Spinal Cord Stimulator (SCS)
7 Global Nerve Stimulator Market by Applications
7.1 Introduction
7.2 Chronic Pain
7.3 Depression
7.4 Dystonia
7.5 Epilepsy
7.6 Parkinson's Disease
8 Global Nerve Stimulator Market by End Users
8.1 Introduction
8.2 Ambulatory Surgical Centers
8.3 Hospital & Clinics
8.4 Trauma Centers
9 Global Nerve Stimulator Market by Regions
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Germany
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
?
9.4 Asia Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Australia
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 UAE
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa
10 Competitive Landscape
10.1 Introduction
11 Company Profile
11.1 Boston Scientific Corporation
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Cochlear ltd.
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Medtronic
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 St Jude Medical, Inc.
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Cyberonics, Inc.
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Aleva Neurotherapeutics SA
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 NeuroPace, Inc.
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments
12 Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.2 Key Companies to Watch
13 Appendix
13.1 Discussion Blue Print